💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Rainbow Children's Medicare Limited is an India-based company, which is engaged in the business of rendering medical and healthcare services. The Company is a multi-specialty pediatric and obstetrics and gynecology hospital operating across approximately 20 hospitals and five…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, slow-growing business, trading cheap versus its own history.
Rainbow Childrens Med is scored on the pharma / healthcare framework. It keeps a healthy 16.1% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.49× reported profit. Free cash flow is worth about 1.3% of its market value.
Over the last 3 years revenue compounded at 13%/yr and profit at 10%/yr. Book value itself has compounded 16%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 17.1%. In the latest quarter profit grew 34% versus the prior quarter.
At 45× earnings, the stock sits at the 9th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price already implies ~19%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 42.35 | 75.62 | better |
| P/B | 7.38 | 3.49 | worse |
| EV/EBITDA | 21.79 | 19.95 | worse |
| ROE | 17.05 | — | — |
| ROCE | 17 | 10.81 | better |
| ROA | 10.09 | 3.84 | better |
| Quick Ratio | 3.33 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 13% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Net profit has risen every year — the hallmark of a compounder. Revenue is outpacing profit (13% vs 10%) — costs are rising faster than the top line.
Operating margin has compressed from 23% to 21% — costs or competition are eating into profitability. Margins have declined for 3 consecutive years — watch for a structural cost problem.
ROE at 17% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 9% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.5× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 15% sequentially — momentum is building. Run-rate stepping up — recent quarters average 13% above earlier ones.
Profit jumped 34% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 49.8% — dispersed ownership; institutional flows drive the stock. FIIs trimmed 4.6pp — foreign money is rotating out. MF holding up 3.3pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.